Loading quotes...
Forecast
| Buy |
Â
3 |
| Hold |
Â
0 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -2.28m | 34.32% |
| EBITDA | -2.28m | 34.32% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | âŹ4.85m |
Number of shares | 5.56m |
52-week high/low | âŹ6.86 - âŹ0.84 |
| Dividends | No |
Beta | -2.05 |
P/E ratio | -0.34 |
PEG ratio | 0.00 |
P/B ratio | 0.00 |
P/S ratio | 0.00 |
Company profile
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
| Name | Acurx Pharmaceuticals Inc Ordinary Shares |
| CEO | David Luci |
| Website | |
| IPO | 25/06/2021 |
| Employees | 4 |